

Lepu Medical Technology (Beijing) Co., Ltd.

2024 Third Quarter Report

The Company and all members of the Board of Directors guarantee that the information disclosed herein is true, accurate, and complete, with no false records, misleading statements, or significant omissions.

Important Content Highlights:

1. The Board of Directors, the Board of Supervisors, directors, supervisors, and senior executives of the Company shall guarantee the truthfulness, accuracy and completeness of the content of the quarterly report, without any false records, misleading statements or material omissions, and also assume several and joint legal liabilities.
2. The head of the Company, person in charge of accounting and person in charge of accounting department (accounting supervisor) hereby declare that: the financial information disclosed in the quarterly report is true, accurate and complete.
3. Whether the Third Quarter Report has been audited

Yes No

I. Key Financial Data

(I) Major accounting data and financial indexes

Whether the Company needs to retrospectively adjust or restate previous annual accounting data?

Yes No

	Current reporting period	Increase or decrease in the current reporting period compared to the same period last year	From the beginning of the year to the end of the reporting period	Increase or decrease from the beginning of the year to the end of the reporting period compared to the same period last year
Operating revenue (RMB)	1,401,585,073.03	-28.41%	4,785,471,627.57	-23.55%
Net profits attributable to shareholders of the listed companies (RMB)	105,413,614.27	-73.12%	802,655,886.18	-40.70%
Net profits attributable to shareholders of the listed companies after deducting non-recurring profits and losses (RMB)	86,927,048.85	-77.19%	734,074,379.16	-42.91%
Net amount of cash flows from operating activities (RMB)	--	--	423,055,774.84	-29.93%
Basic earnings per share (RMB/share)	0.0570	-72.92%	0.4339	-40.30%
Diluted earnings per share	0.0570	-72.92%	0.4339	-40.21%

(RMB/share)				
Weighted average rate of return on net assets	0.66%	Reduce by 1.80 percentage points	5.01%	Reduce by 3.83 percentage points
	End of current reporting period	End of the last year	Increase or decrease at the end of the current reporting period compared to the end of last year	
Total assets (RMB)	25,006,284,390.10	25,022,331,486.69	-0.06%	
Owners' equities attributable to shareholders of the Company (RMB)	15,797,277,277.72	15,976,101,963.31	-1.12%	

(II) Items and amounts of non-recurring profits or losses
 Applicable Not applicable

Unit: RMB

Item	Amount in the current reporting period	Amount from the beginning of the year to the end of the reporting period	Description
Profits and losses on disposal of non-current assets (including the write-off of provision for asset impairment)	142,602.88	7,875,165.96	
Government subsidies included in current profits and losses except for government subsidies closely related to the normal business operations of Company, in line with national policies and obtained according to established standards and having continuous influence on the profits and losses of the Company	15,640,374.90	49,629,084.31	
Profit or loss on changes in fair values of held-for-trading financial assets and financial liabilities by non-financial enterprises and profit or loss obtained from disposal of financial assets and financial liabilities, except for effective hedging operations associated with the Company's normal operation	-18,377,106.80	-7,833,894.95	
Non-operating revenues and expenditures other than those mentioned above	-9,580,139.35	-10,147,634.09	
Other items of profits and losses that meet the definition of non-recurring profits and losses	27,121,109.45	37,922,330.29	
Minus: Influence number of income tax	-373,627.65	5,976,279.63	
Influenced amount of minority shareholders' equities (after-tax)	-3,166,096.69	2,887,264.87	
Total	18,486,565.42	68,581,507.02	--

Specific situations of other profit and loss items complying with the definition of non-recurring profits or losses:

 Applicable Not Applicable

The Company has no other profit and loss items complying with the definition of non-recurring profits or losses.

Description on situations for defining non-recurring profit and loss items listed in the Explanatory Announcement No.1 on Disclosure of the Information of Companies Offering Their Securities to the Public - Non-recurring Profits and Losses as recurring profits and losses.

 Applicable Not Applicable

There are no cases in which the Company defines non-recurring profit and loss items listed in the Explanatory Announcement

No.1 on Disclosure of the Information of Companies Offering Their Securities to the Public - Non-recurring Profits and Losses as recurring profits and losses.

(III) Details and reasons of changes of major accounting data and financial indexes

Applicable Not applicable

II. Information of Shareholders

1. In the third quarter, the company achieved a revenue of 1401.5851 million yuan. Among them:

The cardiovascular implant intervention business achieved a revenue of 517.3834 million yuan, a year-on-year increase of 14.33%. The operating revenue of coronary artery intervention business was 362.5445 million yuan, a year-on-year increase of 7.79%; The operating revenue of structural heart disease business was 135.7549 million yuan, a year-on-year increase of 57.26%.

Surgical anesthesia business resumed growth, achieving a revenue of 151.8970 million yuan, a year-on-year increase of 26.99%;

The sales of the FDF (Finished Dosage Form) business have stabilized, achieving a revenue of 252.7089 million yuan, and it increased by 1.77% month-on-month and decreased by 63.38% year-on-year.

In the third quarter, the company achieved a net profit attributable to shareholders of the listed company of 105.4136 million yuan, and a net profit attributable to shareholders of the listed company after deducting non recurring gains and losses of 86.9270 million yuan. On the one hand, the company is accelerating its business structure adjustment, continuously focusing on core business, and the large expenses incurred from personnel reset and business reengineering have put pressure on cost control during the period. On the other hand, Shanghai Minwei Biotechnology, the cardiovascular innovation drug company controlled by the company during the year, has made progress in research and development as scheduled this quarter, resulting in a continuous increase in research and development expenses.

In the third quarter, the company achieved a net operating cash flow of 264.1698 million yuan.

2. During the reporting period, the company achieved a cumulative operating revenue of 4785.4716 million yuan, a decrease of 1473.7562 million yuan or 23.55% compared to the same period last year. Among them:

1) The medical device sector achieved a revenue of 2563.3501 million yuan, a year-on-year decrease of 10.48%
Cardiovascular interventional business: achieved operating revenue of 1668.7939 million yuan, a year-on-year increase of 16.10%, of which coronary artery intervention business achieved operating revenue of 1213.1490

million yuan, a year-on-year increase of 9.47%; The structural heart disease business achieved a revenue of 384.6696 million yuan, a year-on-year increase of 54.89%.

Surgical anesthesia business: achieved a revenue of 420.5482 million yuan, a year-on-year increase of 5.38%.

In vitro diagnostic business: achieved a revenue of 276.0507 million yuan, a year-on-year decrease of 52.34%.

2) The pharmaceutical sector achieved a revenue of 1476.3574 million yuan, a year-on-year decrease of 38.90%.

Among them, the raw material medicine business achieved a revenue of 284.8228 million yuan, a year-on-year decrease of 11.51%; The revenue from the FDF business reached 1191.5346 million yuan, a decrease of 43.11% compared to the same period last year.

3) The medical care solution sector achieved a revenue of 745.7641 million yuan, a year-on-year decrease of 23.87%. Among them, Hefei Cardiovascular Hospital achieved a revenue of 119.7587 million yuan, an increase of 15.25% compared to the same period last year.

3. During the reporting period, the company achieved a net profit of 783.3477 million yuan, a net profit attributable to shareholders of the listed company of 802.6559 million yuan, and a net profit attributable to shareholders of the listed company after deducting non recurring gains and losses of 734.0744 million yuan.

During the reporting period, the non recurring income attributable to shareholders of the listed company was 68.5815 million yuan, compared to 67.6707 million yuan attributable to shareholders of the listed company in the same period last year.

4. During the reporting period, the company suffered an investment loss of 11.7140 million yuan, a decrease of 29.2195 million yuan or 71.38% compared to the same period last year. This was mainly due to the impact of the company's gradual acquisition of equity in Shanghai Minwei Biotechnology Co., Ltd. on the confirmed investment income.

5. The fair value change loss of the company during the reporting period was 11.1996 million yuan, an increase of 15.2170 million yuan or 378.78% compared to the fair value change income of 4.0174 million yuan in the same period last year, mainly due to the impact of exchange rate changes on the market value of foreign currency wealth management products held by the company during the reporting period.

6. During the reporting period, the company's asset impairment loss was 19.2851 million yuan, an increase of 13.1875 million yuan or 216.27% compared to the same period last year, mainly due to the company's provision for intangible asset impairment during the reporting period.

7. During the reporting period, the company's asset disposal income was 12.3654 million yuan, an increase of 13.8538 million yuan or 930.80% compared to the same period last year when the asset disposal loss was

1.4884 million yuan. This was mainly due to the increase in income from the company's disposal of fixed assets during the reporting period.

8. During the reporting period, the company's non operating income was 12.0778 million yuan, a decrease of 35.9690 million yuan or 74.86% compared to the same period last year, mainly due to a reduction in government incentives and other subsidies received by the company during the reporting period.

9. During the reporting period, the company's non operating expenses amounted to 19.9146 million yuan, an increase of 13.2748 million yuan or 199.93% compared to the same period last year, mainly due to an increase in inventory damage and scrapping during the reporting period.

10. During the reporting period, the minority shareholders of the company suffered a loss of 19.3082 million yuan, an increase of 68.9338 million yuan, or 138.91%, compared to the minority shareholders' income of 49.6256 million yuan in the same period last year. This was mainly due to the increase in research and development investment in non wholly-owned subsidiaries of the company during the reporting period.

11. During the reporting period, the net outflow of cash flow generated by the company's financing activities was 342.3435 million yuan, an increase of 110.9835 million yuan or 47.97% compared to the same period last year. This was mainly due to a year-on-year increase of 517.6682 million yuan in net inflow of borrowings and 265.5123 million yuan in net outflow of dividends. In addition, a total of 177.4274 million yuan was paid for the repurchase of treasury shares in this period, and there was no such expenditure in the same period last year. During the same period last year, the subsidiary Bingkun Medical received a capital increase of 225.8241 million yuan, and there were no such inflows during this reporting period.

12. At the end of the reporting period, the company's trading financial assets amounted to 412.3622 million yuan, an increase of 137.1584 million yuan or 49.84% compared to the beginning of the year, mainly due to the addition of new wealth management products by the company during the reporting period.

13. At the end of the reporting period, the company's investment in real estate amounted to 440.0406 million yuan, an increase of 143.2664 million yuan or 48.27% compared to the beginning of the year, mainly due to an increase in the number of houses rented out by the company during the reporting period.

14. At the end of the reporting period, the company's fixed assets amounted to 4049.5344 million yuan, an increase of 1236.5720 million yuan or 43.96% compared to the beginning of the year. This was mainly due to the completion of some of the company's ongoing construction projects and their conversion to fixed assets during the reporting period.

15. At the end of the reporting period, the company's under construction projects amounted to 541.2834 million

yuan, a decrease of 1256.0022 million yuan or 69.88% compared to the beginning of the year. This was mainly due to the completion of some of the company's under construction projects and their conversion to fixed assets during the reporting period.

16. At the end of the reporting period, the company's short-term borrowings amounted to 354.3719 million yuan, a decrease of 685.3712 million yuan or 65.92% compared to the beginning of the year, mainly due to the company's adjustment of financing structure during the reporting period.

17. At the end of the reporting period, the company's payable bills amounted to 95.4428 million yuan, a decrease of 72.4749 million yuan or 43.16% compared to the beginning of the year. This was mainly due to the company's use of acceptance bills to settle outstanding balances during the reporting period.

18. At the end of the reporting period, the company's accounts payable amounted to 525.4164 million yuan, a decrease of 335.9505 million yuan or 39.00% compared to the beginning of the year. This was mainly due to the company's continuous payment of unsettled goods from the previous year during the reporting period.

19. At the end of the reporting period, the company's payable employee compensation was 62.2979 million yuan, a decrease of 42.5201 million yuan or 40.57% compared to the beginning of the year, mainly due to the company's payment of bonuses provisioned in the previous year during the reporting period.

20. At the end of the reporting period, the company's tax payable was 113.1843 million yuan, a decrease of 85.9215 million yuan or 43.15% compared to the beginning of the year, mainly due to the decline in value-added tax and corporate income tax caused by the decrease in business volume during the reporting period.

21. At the end of the reporting period, the company's non current liabilities due within one year were 710.3680 million yuan, an increase of 212.3328 million yuan or 42.63% compared to the beginning of the year. This was mainly due to the company's adjustment of financing structure and meeting its medium and long-term funding needs during the reporting period.

22. At the end of the reporting period, the company's long-term borrowings amounted to 2860.6531 million yuan, an increase of 1318.4623 million yuan or 85.49% compared to the beginning of the year. This was mainly due to the company's adjustment of financing structure and meeting its medium-term and long-term funding needs during the reporting period.

At the end of the reporting period, the company's inventory of shares was 608.4923 million yuan, an increase of 177.4274 million yuan or 41.16% compared to the beginning of the year, mainly due to an increase in the company's share repurchases during the reporting period.

(I) Table of Total Number of Common Shareholders and Preferred Shareholders Recovering Voting Rights and Shareholdings of Top Ten Shareholders

Unit: Share

Total number of common shareholders at the end of the reporting period		94,003	Total number of preferred shareholders recovering voting rights at the end of reporting period (if any)		0	
Shareholding Status of the Top Ten Shareholders (Excluding Shares Lent through Transfer Financing Business)						
Shareholders' name	Nature of shareholders	Shareholding ratio	Number of shares held	Quantity of shares with conditions of restriction on sales held	Pledge, marking or freezing information	
					Share status	Quantity
Luoyang Ship Material Research Institute	State-owned legal person	12.98%	244,063,788	0	N/A	0
Pu Zhongjie	Domestic natural person	12.13%	228,074,749	171,056,062	Pledge	182,319,981
WP MEDICAL TECHNOLOGIES, INC	Foreign legal person	6.59%	123,968,600	92,976,450	Pledge	85,000,000
Houde Yimin (Beijing) Investment Management Co., Ltd.	Domestic non-state-owned legal person	3.60%	67,750,000	0	N/A	0
Bank of China Limited - Huabao CSI medical trading open-end index securities investment fund	Others	2.35%	44,220,418	0	N/A	0
Houde Yimin (Ningbo) Investment Management Co., Ltd.	Domestic non-state-owned legal person	1.91%	35,850,000	0	N/A	0
Industrial and Commercial Bank of China Limited - E Fund GEM trading open-end index securities investment fund	Others	1.80%	33,939,528	0	N/A	0
Hong Kong Securities Clearing Company Limited	Foreign legal person	1.75%	32,875,263	0	N/A	0
Agricultural Bank of China Limited - CSI 500 trading open-end index securities investment fund	Others	1.29%	24,199,740	0	N/A	0
Wang Yunyou	Domestic natural person	0.64%	12,008,633	0	N/A	0
Shares Held by Top 10 Shareholders without Restriction on Sales (Excluding Shares Lent through Transfer Financing Business and Restricted Circulation Share)						

Shareholders' name	Quantity of shares without conditions of restriction on sales held	Type and quantity of shares	
		Type of shares	Quantity
Luoyang Ship Material Research Institute	244,063,788	RMB common shares	244,063,788
Houde Yimin (Beijing) Investment Management Co., Ltd.	67,750,000	RMB common shares	67,750,000
Pu Zhongjie	57,018,687	RMB common shares	57,018,687
Bank of China Limited - Huabao CSI medical trading open-end index securities investment fund	44,220,418	RMB common shares	44,220,418
Houde Yimin (Ningbo) Investment Management Co., Ltd.	35,850,000	RMB common shares	35,850,000
Industrial and Commercial Bank of China Limited - E Fund GEM trading open-end index securities investment fund	33,939,528	RMB common shares	33,939,528
Hong Kong Securities Clearing Company Limited	32,875,263	RMB common shares	32,875,263
WP MEDICAL TECHNOLOGIES, INC	30,992,150	RMB common shares	30,992,150
Agricultural Bank of China Limited - CSI 500 trading open-end index securities investment fund	24,199,740	RMB common shares	24,199,740
Wang Yunyou	12,008,633	RMB common shares	12,008,633
Description of associated relationships or concerted actions of the above shareholders	Mr. Pu Zhongjie, WP Medical Technologies, Inc., Houde Yimin (Beijing) Investment Management Co., Ltd. and Houde Yimin (Ningbo) Investment Management Co., Ltd. were persons acting in concert within the meaning of PRC law. There was no relationship between other shareholders of the Company or concerted action as stipulated in Measures for the Administration of Acquisition of Listed Companies (Order No.35 of China Securities Regulatory Commission).		
Description of the top 10 shareholders participating in financing and securities business (if any)	None		

Shareholders holding more than 5% of shares, the top 10 shareholders and the top 10 shareholders with unrestricted shares participating in the refinancing business to lend shares

Applicable Not applicable

Unit: Share

Shareholders holding more than 5% of shares, the top 10 shareholders and the top 10 shareholders with unrestricted shares participating in the refinancing business to lend shares								
Name of shareholder (full name)	Shares held by general and credit account at the beginning of the period		Shares lent on transfer financing business at the beginning of the period and not yet returned		Shares held by general and credit account at the end of the period		Shares lent on transfer financing business at the end of the period and not yet returned	
	Total quantity	Proportion to general capital	Total quantity	Proportion to general capital	Total quantity	Proportion to general capital	Total quantity	Proportion to general capital
Agricultural Bank of China Limited - CSI 500	7,259,900	0.39%	2,129,400	0.11%	24,199,740	1.29%	0	0.00%

trading open-end index securities investment fund								
Industrial and Commercial Bank of China Limited - E Fund GEM trading open-end index securities investment fund	18,199,619	0.97%	41,900	0.00%	33,939,528	1.80%	0	0.00%
Bank of China Limited - Huabao CSI medical trading open-end index securities investment fund	39,250,818	2.09%	52,800	0.00%	44,220,418	2.35%	0	0.00%

Top 10 shareholders and the top 10 shareholders with unrestricted shares changed from the previous period due to lending/returning of refinancing

Applicable Not Applicable

(II) Table of Total Number of the Preferred Shareholders and Shareholdings of Top 10 Preferred Shareholders of the Company

Applicable Not Applicable

(III) Statement of restricted share change

Applicable Not applicable

Unit: Share

Shareholders' name	Beginning shares with conditions of restriction on sales	Quantity of increased shares with conditions of restriction on sales released in current period	Quantity of shares with conditions of restriction on sales increased in current period	Ending shares with conditions of restriction on sales	Reason for restriction	Date of cancellation of the restriction
Pu Zhongjie	171,056,062			171,056,062	Restricted circulation	During Mr. Pu Zhongjie's

					stock held by senior executives	employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
WP MEDICAL TECHNOLOGIES, INC	92,976,450			92,976,450	Pre-sale restricted shares	During Mr. Pu Zhongjie's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Zhang Zhibin	163,125		54,375	217,500	Restricted circulation stock held by senior executives	During Mr. Zhang Zhibin's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Wei Zhanjiang	145,200			145,200	Restricted circulation stock held by senior executives	During Mr. Wei Zhanjiang's employment in the Company, the annual transfer of

						shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Wang Yong	143,775			143,775	Restricted circulation stock held by senior executives	During Ms. Wang Yong's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Feng Xiaoying	5,550			5,550	Restricted circulation stock held by senior executives	During Ms. Feng Xiaoying's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Zheng Guorui	22,500		7,500	30,000	Restricted circulation stock held by senior executives	During Mr. Zheng Guorui's employment in the Company, the annual transfer of shares does not exceed 25% of the total shares

						of the Company, and he will not transfer the shares of the Company within half a year after his resignation.
Total	264,512,662		61,875	264,574,537	--	--

III. Other Major Events

Applicable Not applicable

On August 2, 2024, the Company received the *Decision on Taking Administrative Supervision Measures for Rectification of Lepu Medical Technology (Beijing) Co., Ltd.* ([2024] No.198) issued by Beijing Office of the CSRC (hereinafter referred to as the "Decision"), requiring the Company to conduct self-inspection and rectification on the problems mentioned in the Decision (Announcement No. 2024-079). On August 23, 2024, the Company rectified the related matters and disclosed the self-inspection and rectification announcement (Announcement No. 2024-089) upon review by the Board of Directors.

In August 2024, MemoSorb® biodegradable atrial septal defect occluder independently developed by Shanghai Shape Memory Alloy Material Co., Ltd. under the Company was officially registered and approved by National Medical Products Administration (NMPA) (Announcement No. 2024-080).

On September 6, 2024, the Company held the Tenth Meeting of the Sixth Session of the Board of Directors and the Eighth Meeting of the Sixth Session of the Board of Supervisors, and reviewed and approved the Proposal on *Terminating the Implementation of the 2022 Restricted Stock Incentive Plan*. The Board of Directors decided to terminate the implementation of the 2022 restricted stock incentive plan. In 2022, a total of 18,273,500 second-class restricted shares granted but not yet attributed were invalidated by the Company, and the supporting documents such as the *2022 Restricted Stock Incentive Plan (Revised Draft) and Its Summary*, and the *2022 Restricted Stock Incentive Plan Implementation Assessment Management Measures* were terminated (Announcement No. 2024-098).

On September 20, 2024, the Company distributed a cash dividend of RMB 1.420000 in cash (inclusive of tax) for every 10 shares to all shareholders on the basis of a total share capital of 1,843,394,896 shares after deducting 37,215,700 shares repurchased from a total share capital of 1,880,610,596 shares, amounting to a total of RMB 261,762,075.23 in cash dividends (inclusive of tax), Announcement No. 2024-102.

In September 2024, Mr. Zhang Zhibin, the former General Manager of the Company, and Mr. Zheng Guorui, the former Deputy General Manager of the Company, applied for resignation from their current positions in the Company due to personal reasons, and will no longer hold any position in the Company after their resignation. Upon nomination by the Chairman of the Board of Directors and after the qualification examination by the Nomination Committee of the Board of Directors, the Company convened the Eleventh Meeting of the Sixth Session of the Board of Directors on September 24, 2024, and passed the *Proposal on the Appointment of General Manager of the Company*, agreeing to appoint Ms. Pu Fei as the General Manager of the Company, with a term of office commencing from the date of approval by the current session of the Board of Directors to the date of expiration of the Sixth Session of the Board of Directors (Announcement No. 2024-108).

IV. Quarterly Financial Statements

(I) Financial statements

1. Consolidated balance sheet

Prepared by: Lepu Medical Technology (Beijing) Co., Ltd.

September 30, 2024

Unit: RMB

Item	Balance at the end of the period	Balance at the beginning of the period
Current assets:		
Monetary capital	3,340,861,662.25	4,220,754,806.78
Deposit reservation for balance		
Lending funds		
Trading financial assets	412,362,206.34	275,203,779.61
Derivative financial assets		
Notes receivable	102,456,414.54	84,509,973.95
Accounts receivable	1,898,862,176.81	1,753,160,708.35
Receivables financing	107,981,361.66	83,407,668.79
Advance payment	301,135,787.35	320,471,238.27
Premium receivable		
Reinsurance account receivable		
Provision of cession receivable		
Other receivables	142,672,052.49	110,449,885.41
Including: Interests receivable		
Dividends receivable		
Purchase of financial assets for resale		
Inventory	2,216,459,996.88	2,289,473,586.38
Including: Data resource		
Contract assets		
Held-for-sale assets		
Non-current assets due within one year	2,235,269.54	3,302,070.61
Other current assets	207,609,262.17	184,703,896.89
Total current assets	8,732,636,190.03	9,325,437,615.04
Non-current assets:		

Loan and advance payment issuance		
Creditors' investments		
Other creditors' investments		
Long-term accounts receivable	935,793.46	2,968,556.17
Long-term equity investments	1,200,559,023.47	1,353,760,737.79
Other equity instrument investments	1,100,654,095.83	1,190,240,450.59
Other non-current financial assets	26,500,000.00	26,500,000.00
Investment real estate	440,040,580.08	296,774,138.94
Fixed assets	4,049,534,377.67	2,812,962,375.74
Engineering in progress	541,283,433.55	1,797,285,664.72
Productive biological assets		
Oil-gas assets		
Right-of-use assets	362,963,401.57	326,430,233.20
Intangible assets	1,701,520,199.79	1,817,546,203.28
Including: Data resource		
Development expenditures	1,008,359,063.69	861,745,696.38
Including: Data resource		
Goodwill	3,841,657,674.79	3,504,330,628.08
Long-term unamortized expenses	310,650,492.41	256,771,874.86
Deferred income tax assets	166,667,350.55	167,324,190.66
Other non-current assets	1,522,322,713.21	1,282,253,121.24
Total non-current assets	16,273,648,200.07	15,696,893,871.65
Total assets	25,006,284,390.10	25,022,331,486.69
Current liabilities:		
Short-term loans	354,371,906.57	1,039,743,103.15
Borrowings from the Central Bank		
Borrowing funds		
Trading financial liabilities		
Derivative financial liabilities		
Notes payable	95,442,845.16	167,917,721.65
Accounts payable	525,416,430.21	861,366,956.73
Advance receipt		
Contract liabilities	237,507,441.67	269,519,519.47
Sale of financial assets for buyback		
Deposits from customers and interbank		
Acting trading securities		
Acting underwriting securities		
Employee remuneration payable	62,297,871.17	104,817,928.71
Tax payables	113,184,344.96	199,105,826.66
Other payables	463,554,853.84	555,678,277.77
Including: Interests payable		
Dividends payable	21,753,503.56	3,353,503.56
Service charges and commissions payable		
Reinsurance account payable		
Held-for-sale liabilities		
Non-current liabilities due within one year	710,367,999.34	498,035,202.06
Other current liabilities	65,538,130.74	62,471,403.25
Total current liabilities	2,627,681,823.66	3,758,655,939.45
Non-current liabilities:		
Insurance contract reserves		
Long-term loans	2,860,653,053.85	1,542,190,754.84
Bonds payables	1,592,677,302.71	1,560,810,898.63
Including: Preferred shares		

Perpetual bonds		
Lease liabilities	288,732,716.72	269,967,672.04
Long-term accounts payable		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred revenues	148,406,712.28	195,216,181.81
Deferred income tax liabilities	186,831,475.44	197,934,919.32
Other non-current liabilities		
Total non-current liabilities	5,077,301,261.00	3,766,120,426.64
Total liabilities	7,704,983,084.66	7,524,776,366.09
Owners' equities:		
Share capital	1,880,610,599.00	1,880,610,352.00
Other equity instruments	214,748,648.84	214,751,048.51
Including: Preferred shares		
Perpetual bonds		
Capital reserves	3,527,580,539.85	3,464,665,903.83
Minus: Treasury shares	608,492,292.32	431,064,877.67
Other comprehensive revenues	-92,228,667.37	-80,892,863.74
Special reserves		
Surplus reserves	732,541,206.45	732,541,206.45
General risk reserves		
Undistributed profits	10,142,517,243.27	10,195,491,193.93
Total owners' equities attributable to the parent company	15,797,277,277.72	15,976,101,963.31
Equity attributable to minority shareholders	1,504,024,027.72	1,521,453,157.29
Total owners' equities	17,301,301,305.44	17,497,555,120.60
Total Liabilities and Owners' Equities	25,006,284,390.10	25,022,331,486.69

Legal Representative: Pu Zhongjie

Principal of accounting work: Wang Yong

Person in charge of accounting: Li Yun

2. Consolidated income statement from the beginning of the year to the end of the reporting period

Unit: RMB

Item	Amount incurred in the current period	Amount incurred in the previous period
I. Gross operating revenues	4,785,471,627.57	6,259,227,849.28
Including: Operating revenue	4,785,471,627.57	6,259,227,849.28
Interest Incomese		
Earned premium		
Incomes from service charges and commissions		
II. Total Operating Costs	3,880,756,982.24	4,727,014,426.22
Including: Operating costs	1,780,228,328.80	2,184,268,805.05
Interest expenses		
Expenditures for service charges and commissions		
Surrender value		
Net amount of compensation expenses		
Withdrawal of net amount of insurance liability reserve		
Policy dividends expenses		
Reinsurance expenses		

Taxes and surcharges	58,830,236.87	66,174,243.53
Sales expenses	973,676,025.69	1,193,544,744.18
Management expenses	476,245,778.76	564,543,747.14
Research and development expenses	557,054,487.38	674,829,181.31
Financial expenses	34,722,124.74	43,653,705.01
Including: Interest expenses	128,195,183.80	124,508,597.81
Interest Income	84,464,783.54	88,974,288.07
Plus: Other revenues	56,393,787.57	65,288,597.24
Investment revenues (the loss is expressed with "-")	-11,713,964.66	-40,933,488.02
Including: Revenues from investment in associated enterprises and joint ventures	-54,466,058.59	-44,413,677.84
Revenues from derecognition of financial assets measured at the amortized costs		
Exchange gains (the loss is expressed with "-")		
Revenues from net exposure hedging (the loss is expressed with "-")		
Revenues from changes in fair value (the loss is expressed with "-")	-11,199,598.89	4,017,391.60
Losses from credit impairment (the loss is expressed with "-")	-20,531,077.42	-21,516,916.12
Losses from asset impairment (the loss is expressed with "-")	-19,285,127.32	-6,097,593.05
Revenues from assets disposal (the loss is expressed with "-")	12,365,443.28	-1,488,369.54
III. Operating profits (the loss is expressed with "-")	910,744,107.89	1,531,483,045.17
Plus: Non-operating revenue	12,077,822.49	48,046,821.07
Minus: Non-operating expenditures	19,914,620.43	6,639,797.09
IV. Total profits (total loss is expressed with "-")	902,907,309.95	1,572,890,069.15
Minus: Income tax expenses	119,559,657.34	169,663,705.13
V. Net profits (net loss is expressed with "-")	783,347,652.61	1,403,226,364.02
(I) Classified by operation continuity		
1. Net profit from continuing operation (the net loss is expressed in with "-")	783,347,652.61	1,403,226,364.02
2. Net profit from discontinuing operation (the net loss is expressed in with "-")		
(II) Classification by ownership		
1. Net profit attributable to the shareholders of parent company (the net loss is expressed with "-")	802,655,886.18	1,353,600,791.72
2. Minority shareholders' profit and loss (the net loss is expressed with "-")	-19,308,233.57	49,625,572.30
VI. After-tax net amount of other	-9,909,358.96	66,172,162.22

comprehensive incomes		
After-tax net amount of other comprehensive incomes attributable to the owners of the parent company	7,488,657.40	80,156,115.00
(I) Other comprehensive incomes that cannot be reclassified into profits and losses	-21,837,814.68	71,080,109.59
1. Re-measurement of the changed amount of the defined benefit plan		
2. Other comprehensive revenues that cannot be converted into the profits and losses under the equity method		
3. Changes in fair value of other equity instrument investments	-21,837,814.68	71,080,109.59
4. Changes in fair value of enterprise credit risk		
5. Others		
(II) Other comprehensive incomes that can be reclassified into profits and losses	29,326,472.08	9,076,005.41
1. Other comprehensive revenues that can be converted into the profits and losses under the equity method	107,248.25	97,631.32
2. Changes in fair value of other creditor's right investments		
3. Amounts of financial assets reclassified into other comprehensive incomes		
4. Credit impairment reserves of other creditor's right investments		
5. Cash flow hedging reserves		
6. Conversion difference in foreign currency financial statement	29,219,223.83	8,978,374.09
7. Others		
After-tax net amount of other comprehensive incomes attributable to the minority shareholders	-17,398,016.36	-13,983,952.78
VII. Total comprehensive revenues	773,438,293.65	1,469,398,526.24
(I) Total comprehensive incomes attributable to the owners of the parent company	810,144,543.58	1,433,756,906.72
(II) Total comprehensive incomes attributable to minority shareholders	-36,706,249.93	35,641,619.52
VIII. Revenues per share:		
(I) Basic earnings per share	0.4339	0.7268
(II) Diluted earnings per share	0.4339	0.7257

As for the business combination under the same control in the current period, the net profit achieved by the combined party before the combination is: RMB 0.00, and the net profit achieved by the acquiree for the prior period is RMB 0.00.

Legal Representative: Pu Zhongjie Principal of accounting work: Wang Yong Person in charge of accounting: Li Yun

3. Consolidated Cash Flow Statement from the Beginning of the Year to the End of the Reporting Period

Unit: RMB

Item	Amount incurred in the current period	Amount incurred in the previous period
I. Cash flow from operating activities:		

Cash received from the sales of goods or rendering of services	4,696,328,560.08	6,143,186,672.37
Net increase amount in customer deposits and interbank deposits		
Net increase amount in borrowings from the Central Bank		
Net increase amount in borrowing funds from other financial institutions		
Cash received from the original insurance contract premium		
Net amount of cash received from reinsurance premiums		
Net increase amount in insured deposit and investment		
Cash collected from interests, service charges and commissions		
Net increase amount in borrowing funds		
Net increase amount in repurchase business funds		
Net cash amount received from vicariously traded securities		
Refund of tax and dues received	77,544,152.69	130,198,620.52
Cash received from other operating activities	126,543,039.70	151,370,828.07
Subtotal of cash inflow from operating activities	4,900,415,752.47	6,424,756,120.96
Cash paid for goods purchased and labor services received	1,376,028,882.19	1,996,815,069.17
Net increase amount in customer loans and advances		
Net increase amount in deposit in the Central Bank and interbank payments		
Cash paid for the claim payment of the original insurance contract		
Net increase amount in lending funds		
Cash paid for interests, service charges and commissions		
Cash paid for policy dividends		
Cash paid to and for employees	1,485,480,041.72	1,745,226,054.50
Tax and dues paid	692,077,220.13	841,197,288.35
Other cash paid related to operating activities	923,773,833.59	1,237,735,529.27
Subtotal of cash outflow from operating activities	4,477,359,977.63	5,820,973,941.29
Net amount of cash flows from operating activities	423,055,774.84	603,782,179.67
II. Cash flow from investing activities:		
Cash received from recouping investments	274,915,053.42	445,036,872.14
Cash received from investment revenues	31,342,572.41	159,232,489.89
Net amount of cash received from	30,004,465.17	6,435,678.29

disposal of fixed assets, intangible assets and other long-term assets		
Net amount of cash received from disposal of subsidiaries and other business units	15,250,149.21	
Other cash received related to investing activities	12,235,724.68	6,153,094.04
Subtotal of cash inflow from investing activities	363,747,964.89	616,858,134.36
Cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets	503,806,832.55	697,817,454.96
Cash paid for investments	617,387,754.10	528,671,461.10
Net increase in pledge loans		
Net amount of cash paid for acquisition of subsidiaries and other business units	25,092,671.89	228,593,672.92
Other cash paid related to investing activities	201,212,711.38	239,774,416.28
Subtotal of cash outflow from investing activities	1,347,499,969.92	1,694,857,005.26
Net amount of cash flows from investing activities	-983,752,005.03	-1,077,998,870.90
III. Cash flow from financing activities:		
Cash received from absorbing investments	1,260,000.00	225,824,124.80
Including: Cash received from subsidiaries absorbing minority shareholders' investments	1,260,000.00	225,824,124.80
Cash received from obtaining borrowings	3,098,484,319.32	2,540,612,016.00
Other cash received related to financing activities	46,487,465.09	51,848,096.35
Subtotal of cash inflow from financing activities	3,146,231,784.41	2,818,284,237.15
Cash paid for the repayment of debts	2,151,029,148.82	2,110,825,000.00
Cash paid for the distribution of dividends, profits or repayment of interests	997,283,770.02	760,967,533.27
Including: Dividends and profits paid by subsidiaries to minority shareholders	33,066,453.82	11,179,110.35
Other cash paid related to financing activities	340,262,368.82	177,851,731.49
Subtotal of cash outflow from financing activities	3,488,575,287.66	3,049,644,264.76
Net amount of cash flows from financing activities	-342,343,503.25	-231,360,027.61
IV. Impact of exchange rate change on cash and cash equivalents	-1,568,672.71	-18,931,935.07
V. Net increase amount in cash and cash equivalents	-904,608,406.15	-724,508,653.91
Plus: Beginning balance of cash and cash equivalents	4,099,954,989.87	5,309,297,789.78
VI. Ending balance of cash and cash equivalents	3,195,346,583.72	4,584,789,135.87

(II) Implementation of the adjustment of new accounting standards, and the financial statement related items at the beginning of the year for the first time from 2024

Applicable Not Applicable

(III) Audit report

Whether the Third Quarter Report has been audited

Yes No

The Company's Third Quarter Report has not been audited.

Board of Directors of Lepu Medical Technology (Beijing) Co., Ltd.

October 25, 2024